Ubs Asset Management Americas Inc Vaxcyte, Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 408,274 shares of PCVX stock, worth $35.1 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
408,274
Previous 295,762
38.04%
Holding current value
$35.1 Million
Previous $22.3 Million
108.72%
% of portfolio
0.01%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding PCVX
# of Institutions
352Shares Held
122MCall Options Held
775KPut Options Held
433K-
Vanguard Group Inc Valley Forge, PA11.4MShares$983 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$939 Million0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$854 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$747 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$421 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $5.1B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...